Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
BERKELEY HEIGHTS, N.J., Feb. 02, 2016 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 18th Annual BIO CEO & Investor Conference on February 8 at 10:30 a.m. EST at the Waldorf Astoria in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs.
A live webcast of the presentation will be available through the Company's corporate website: www.cyclacel.com. The webcast will be archived for 90 days.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including BRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor in a Phase 1 study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for more information.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
© Copyright 2016 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
Contacts for Cyclacel Pharmaceuticals, Inc. Company: Paul McBarron, (908) 517-7330, [email protected] Investor Relations: Russo Partners LLC, Robert Flamm, (212) 845-4226, [email protected]
